Compare Cytokinetics Inc (CYTK) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Alphabet Inc Class A — how do they compare? Cytokinetics Inc trades at $62.74 (market cap $8.62B), while Alphabet Inc Class A trades at $352.46 (market cap $4.24T). The key difference: Alphabet Inc Class A is far larger — about 491.9× Cytokinetics Inc's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | GOOGL | |
|---|---|---|
Market Cap | $8.62B | $4.24T |
Volume | 2,594,626 | 23,392,850 |
Sector | Health | Media |
52-Week High | $87.26 | $402.62 |
52-Week Low | $54.76 | $236.59 |
Typical Hold Time | 19 Days | — |
Enterprise Value | $8.72B | $4.13T |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
Alphabet (GOOGL) trades at $353.47, up 0.85% with strong bullish momentum. The stock shows robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Technical indicators signal bullish momentum with the current price above key support levels. Recent earnings beats and strong analyst consensus support continued upside potential.
Outlook remains positive with 87% analyst buy ratings and $431.83 price target representing 22% upside. Key risks include antitrust scrutiny and AI competition, but Alphabet's diversified revenue streams and strong cash flow position the company for sustained growth. The combination of technical strength and fundamental excellence suggests favorable risk-reward for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
